Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 34 and last traded at GBX 35, with a volume of 48944 shares. The stock had previously closed at GBX 35.
Faron Pharmaceuticals Oy Trading Up 2.9%
The firm has a 50-day moving average of GBX 39.49 and a 200 day moving average of GBX 42.76. The company has a current ratio of 2.40, a quick ratio of 1.09 and a debt-to-equity ratio of 154.15. The stock has a market capitalization of £73.04 million, a price-to-earnings ratio of -3.13 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
- MarketBeat Week in Review – 09/14 – 09/18
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
